The current role of sentinel node biopsy in the management of melanoma | 60 min
Identification and biopsy of the sentinel lymph node can help correctly indicate whether melanoma has spread beyond the primary site, which is one of the most powerful prognostic indicators for cutaneous melanoma.FACULTY
This engaging interactive learning module will help you understand the current role of sentinel node biopsy (SNB) in the management of melanoma, provide an overview of the procedure and outline the Australian guidelines. It also discusses the evolution of the management of clinically node negative melanoma and describes the role of SNB in practice today, including identifying patients who benefit from SNB.
This learning module is suitable for Surgical Oncologists, General Surgeons, Plastic Surgeons, Dermatologists, Skin Cancer GPs and General GPs.
Note: This module is the first stage of the comprehensive SNB Training Course for surgeons. Stage II and III are due to be complete in early 2023. Register your interest as the first to be notified.
A Statement of Completion will be provided at the end of this module for your CPD records.
Prof Andrew Spillane Surgical Oncologist, Melanoma Institute Australia | Professor of Surgical Oncology, The University of Sydney Declaration of Interest A/Prof David Gyorki Consultant Surgeon, Peter MacCallum Cancer Centre Dr Christopher Allan Consultant Surgeon, Mater Private Hospital |Senior Lecturer, The University of Queensland Prof John Thompson AO Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Declaration of Interest
- Dr Jonathan Moore – General Practitioner
- A/Prof Alexander Menzies – Medical Oncologist
- A/Prof Sydney Ch’ng – Plastic and Reconstructive Surgeon
- A/Prof Robyn Saw – General Surgeon
- Dr Alexander Varey – Plastic and Reconstructive Surgeon
- Dr Kevin London – Nuclear Medicine Specialist
- Kim Ioannou – Chief Nuclear Medicine Scientist
- Danielle Fischer – Education Program Manager
- Identify patients who may benefit from SNB.
- Detail the best practice method for performing SNB that provides the most accurate assessment of possible subclinical melanoma spread to regional lymph nodes.
- Describe the implications for management of the information gained from SNB, including how a positive SNB result identifies relevant patients for Pharmaceutical Benefits Scheme (PBS)-approved systemic adjuvant therapy or a clinical trial.
- Summarise the importance of working with a multidisciplinary team to improve melanoma management and patient outcomes.
- Completing this learning module will accrue 3 Category 1 CPD points per hour for Fellows of The Australasian College of Dermatologists.
This educational activity has been approved in the RACS CPD Program. Fellows who participate can claim 1 point per hour in Education. Participation in this activity will be populated into your RACS CPD Online. This activity (395002) is allocated 1 EA CPD hour in the RACGP 2023-25 CPD Program. This activity (28604) has been accredited in the 2023 – 2025 ACRRM PD Program for 1 Educational Activity Hour. This learning module was proudly supported through unrestricted educational grants from:
current role of SLNB in melanoma managementGreat, succinct, informative module. Dispels myths and misconceptions regarding SLNB and gives a great framework for use of knowledge gained in clinical practice.